Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 253 participants.

Also called NCT02401243

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 253 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02401243
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02401243. Randomized; no masking; primary purpose treatment. Start 2015-03 (registry gives no type); primary completion 2016-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients
Acronym
TITRATION
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
INSULIN GLARGINE (U300)
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct02401243
Content hash
a7930430ce9fb23d9e8b84c9c1ba9e97b3122d7bb9c6130bb9e4e995aceeae64